Kate Haviland
About Kate Haviland
Kate Haviland is the President and CEO of Blueprint Medicines, with a strong background in biochemistry, molecular biology, and economics from Wesleyan University, and an MBA from Harvard Business School.
Kate Haviland: President and Chief Executive Officer
Kate Haviland currently serves as the President and Chief Executive Officer. In her role, she leverages her extensive background in biochemistry, molecular biology, and economics to lead the company's strategic initiatives. Haviland's leadership is characterized by her strategic vision and her ability to drive transformative growth.
Kate Haviland's Education and Expertise
Kate Haviland holds a Bachelor of Arts from Wesleyan University, where she majored in biochemistry/molecular biology and economics. Furthering her education, she earned an M.B.A. from Harvard Business School. These academic credentials support her robust understanding of both the scientific and business aspects of her industry.
Background of Kate Haviland
Kate Haviland has had a distinguished career in the biopharmaceutical sector. She has held key leadership roles at several companies, including Idera Pharmaceuticals, Sarepta Therapeutics, PTC Therapeutics, and Genzyme. Her extensive experience spans various critical functions such as corporate development, commercial strategy, and technical operations, making her a well-rounded leader in the field.
Achievements of Kate Haviland
During her tenure at Blueprint Medicines, Kate Haviland was instrumental in forming and executing the company's business development strategy. As the founding chair of the portfolio management team, she played a crucial role in driving global capital investment plans and capital market financings. Her efforts were pivotal in the transformative growth of Blueprint Medicines. Additionally, she manages important functions like portfolio strategy and corporate affairs.
Kate Haviland's Board Memberships
Kate Haviland serves on the Board of Directors of Bicara Therapeutics and is the Chair of the Board of Directors of Fulcrum Therapeutics. In these roles, she contributes her expertise in audit and corporate governance to guide the strategic direction of these companies. Her involvement underscores her commitment to advancing the biopharmaceutical industry.